|Bid||0.6102 x 800|
|Ask||0.6176 x 2200|
|Day's range||0.6100 - 0.6999|
|52-week range||0.4600 - 3.8900|
|Beta (5Y monthly)||2.08|
|PE ratio (TTM)||N/A|
|Earnings date||14 Mar 2022 - 18 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.21|
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
CAMBRIDGE, Mass., May 17, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.
Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?